Upgrade Control System for SUPPO Machine Novartis pharma

Upgrade Control System for SUPPO Machine

Technical Specifications

ClientNovartis pharma
Project CodeS16773
Commissioning2026
CountryEgypt
IndustryPharma
Scope of Work
Documentation CFR_21 compliance PLC programming SCADA programming
Main Contractor
EISAC AUTOMATION

Results & Improvements

EISAC Automation, acting as the Main Contractor, successfully delivered a high-precision control system modernization for the SUPPO production machine at Novartis Pharma in the UAE (Project S16773). The project focused on transforming the machine's automation architecture into a fully compliant, high-performance system within the pharmaceutical industry. The scope of work encompassed advanced PLC and SCADA programming, specifically engineered to provide seamless operation and real-time monitoring of critical manufacturing parameters. A key pillar of this execution was ensuring full CFR 21 Part 11 compliance, implementing secure electronic records, comprehensive audit trails, and strict data integrity protocols required for international regulatory audits. Backed by rigorous technical documentation, this upgrade ensures Novartis's production line operates with maximum reliability, precision, and adherence to the most stringent global pharmaceutical standards.

Project Overview

EISAC Automation, acting as the Main Contractor, successfully delivered a high-precision control system modernization for the SUPPO production machine at Novartis Pharma in the UAE (Project S16773). The project focused on transforming the machine's automation architecture into a fully compliant, high-performance system within the pharmaceutical industry. The scope of work encompassed advanced PLC and SCADA programming, specifically engineered to provide seamless operation and real-time monitoring of critical manufacturing parameters. A key pillar of this execution was ensuring full CFR 21 Part 11 compliance, implementing secure electronic records, comprehensive audit trails, and strict data integrity protocols required for international regulatory audits. Backed by rigorous technical documentation, this upgrade ensures Novartis's production line operates with maximum reliability, precision, and adherence to the most stringent global pharmaceutical standards.

Need a Similar Solution? WhatsApp Us